Top Pharmaceutical Companies in Los Angeles, CA (91)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer and other urologic diseases.
reach52 is a Singapore-based healthtech social enterprise on a mission to redesign healthcare to reach the 52% of the world currently without access. They operate a fully integrated healthcare delivery model in emerging markets, leveraging community health educators and data-driven insights to provide affordable medicines, screening services, and health interventions through partnerships with governments, businesses, and social organizations.
Sinclair is a global medical aesthetics company that specializes in manufacturing and commercializing a wide portfolio of injectable and EBD treatments to support a consumer's full aesthetic journey. As a wholly owned subsidiary of Huadong Medicine Company Limited, the company's products are available in more than 55 countries through a direct presence in key global markets and a network of...
Sinclair's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sinclair is positioned as a top-tier U.S. broadcaster with one of the largest station portfolios and owned networks that extend national reach. It is widely characterized as a leading player in local TV and sports content, even as Nexstar holds the top spot.
Strong Revenue Growth: Recent 2026 quarters show year-over-year revenue gains and higher full-year guidance, supported by stronger political demand, improving local media trends, and stable distribution. Digital-led core advertising is noted as a contributor to the uptick.
Innovation-Driven Growth: The company plays a leading role in ATSC 3.0/NextGen TV through ONE Media and continues to build specialty assets such as Tennis Channel. These initiatives broaden technology and content platforms that can diversify growth beyond legacy broadcast.
Clínica Monseñor Oscar A. Romero is a 501(c)(3) nonprofit Federally Qualified Health Center (FQHC) dedicated to providing quality, affordable, and culturally sensitive healthcare to underserved communities in greater Los Angeles. The clinic offers medical, dental, vision, pharmacy, and behavioral health services regardless of a patient's ability to pay, while honoring the legacy and teachings of Monseñor Oscar A. Romero.
Edwards Lifesciences (NYSE: EW), is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales &...
Edwards Lifesciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: Edwards is broadly characterized as the TAVR category leader anchored by the SAPIEN portfolio, and its first-to-approval EVOQUE tricuspid replacement reinforces leadership across structural heart. Industry trackers and company updates point to durable share and breadth across aortic, mitral, and tricuspid therapies.
Strong Revenue Growth: Recent results show double-digit top-line expansion and successive raises to the 2026 sales outlook, driven by steady TAVR demand and rapid TMTT growth. Management commentary emphasizes continued momentum with a consistent long-term growth ambition.
Innovation-Driven Growth: First-to-approval EVOQUE in tricuspid replacement, rapid uptake of PASCAL in mitral repair, and extensive long-term SAPIEN evidence position the portfolio for further adoption. Regulatory and policy catalysts, including a pending CMS TAVR coverage reconsideration and accumulating durability data, may expand access.
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as...
Daiichi Sankyo's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate sustained year-over-year revenue increases driven primarily by the oncology franchise, notably ENHERTU and DATROWAY. Management maintains forward revenue growth guidance while highlighting continued indication and geographic expansion for these assets.
Strategic Partnerships: Large, multi‑asset collaborations with AstraZeneca and Merck validate the DXd platform and provide capital, development support, and commercial reach. These alliances underpin scale‑up and reinforce the medium‑term growth outlook in oncology.
Strong Market Position & Advantage: The company is recognized as a leader in oncology antibody‑drug conjugates, with ENHERTU establishing leading shares in key indications and additional approvals broadening use. Category leadership is further supported by expanding first‑line and tumor‑agnostic indications.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have...
.png)
Sleuth is a startup that delivers done-for-you competitive intelligence insights and reports to biopharma companies and investors. We use AI agents and a proprietary database of over 100M data points and documents to power bespoke analyses for executives and a range of business-focused teams across the industry. Among our current customers are some of the largest pharma companies in the...
Amerita, Inc. is a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. This market is expanding rapidly and is driven by increasing healthcare costs that are moving patients into the most cost-effective delivery settings, a growing bio-pharmaceutical pipeline of
Lumena Pharmaceuticals develops oral therapeutics for rare liver diseases to improve liver function and relieve disease symptoms.
Mixlab is the first modern, tech-enabled pet pharmacy that focuses on creating custom medications and delightful experiences for pets, their parents and veterinarians. By putting service at the heart of everything we do, our talented team is able to provide the best personalized care for our patients, as well as those who care for them.
Mixlab's Top Stability & Growth Strengths
Market Expansion: The company expanded from a few labs to a multi‑site footprint across NY, CA, FL, TX, and WI with shipping to all 50 states and same‑/next‑day options in select markets. Acquisitions in 2024–2025 (e.g., NexGen, The Pet Apothecary, SBH Medical’s veterinary business) broadened geographic coverage and capacity.
Investor Backing & Capital Strength: Recent capital raises, including a $10M round in 2023, funded nationwide scaling and platform development. Investor support is tied to new facilities and acquisitions that extend operational reach.
Innovation-Driven Growth: Technology integrations (e.g., Vetcove, Vetsource, Instinct EMR), a new client portal, and launch of an AI health partner (Maisy) underpin a tech‑first growth strategy. The model emphasizes a modern, veterinary‑friendly digital workflow and fast fulfillment.
Seragon is a research-based biopharmaceutical company, committed to innovating cutting-edge discoveries in biotechnology and medicine.
Meissner manufactures advanced microfiltration and single-use systems. Focused on fluid technology and innovation, we leverage our R&D efforts to offer our clients products that deliver advanced processing and fluid handling solutions for pharmaceutical and biopharmaceutical manufacturing. To find out more about Meissner, visit www.meissner.com. If you are interested in pursuing a career at Meissner, please visit www.meissner.com/careers.
Best Formulations is a contract manufacturer specializing in the development and production of nutraceuticals, dietary supplements, and personal care products. Founded in 1984, the company provides manufacturing services for vitamins, minerals, and plant-based nutritional supplements. Following its acquisition by Sirio Pharma, it serves as a key manufacturing hub for global health and wellness brands, with operations spanning nutraceuticals and beauty...
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases.
Best Formulations is a California-based contract manufacturer specializing in the development and commercialization of nutraceuticals, pharmaceutical products, and dietary supplements. Founded in 1984, the company is one of the largest producers of plant-based softgels in the United States. Now part of Sirio Pharma, it provides turnkey solutions, including proprietary formulations and vertically integrated manufacturing and packaging for the health and...
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically...
986 Pharmacy is a group of independent community pharmacies operating under 986 Degrees Corporation, serving patients in California and beyond. Its offerings span everyday prescriptions, specialty medications, compounding, and infusion services, alongside vaccinations, medication therapy management, synchronized refills, and free local delivery. The company emphasizes personalized, clinically informed care, multilingual support, and service to Medicare and Medicaid patients, assisted-living facilities,...
Founded in 1955 and based in Long Beach, California, we are one of the largest independent owners, suppliers and operators of gas stations and convenience stores in the Western United States. We have over 3,500 Team Members in more than 450 locations spread across California, Oregon, Washington and Colorado and we're still growing! We offer fuel under the 76, Conoco,...
United Pacific's Top Stability & Growth Strengths
Strong Market Position & Advantage: United Pacific/Rocket is a top-15 U.S. chain by store count and a clear regional leader in the Western U.S., supported by a unified Rocket c-store brand across company-operated sites. This scale in a fragmented market provides meaningful presence even if it is not among the top national giants.
Market Expansion: Recent growth into the mid-600s stores, the CF United combination with Alta Convenience, and targeted acquisitions expanded the footprint to 11 states and reduced reliance on Southern California. Momentum includes indications of expansion into the Rockies/Midwest alongside selective bolt-on deals.
Innovation-Driven Growth: Rollouts of e-commerce, retail media, and pump-to-store conversion tools (e.g., Lula Commerce and Upside) across 600+ locations indicate above-average tech adoption for a regional chain. Digital enablement and brand consolidation support ongoing modernization and same-store growth.
